Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192023
Status:
COMPLETED
Last Update Posted:
2010-01-18
First Post:
2005-09-12
Brief Title:
An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-DeficitHyperactivity Disorder ADHD and Comorbid Oppositional Defiant Disorder ODD
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
An Italian Randomised Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-DeficitHyperactivity Disorder and Comorbid Oppositional Defiant Disorder
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a phase IIIb multicentre randomised placebo controlled trial in paediatric patients with Attention-DeficitHyperactivity ADHD and Oppositional Defiant Disorder ODD The primary aim of the study is to evaluate the efficacy of atomoxetine in improving ADHD and ODD symptoms in patients non responders to a previous psychological intervention with parent support Moreover the potential role of atomoxetine in treating other psychiatric comorbid conditions associated with ADHD and ODD will be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B4Z-IT-LYCY | OTHER | Eli Lilly and Company | None |